Newark, Calif.-based StemCells announced positive interim data from its Phase 2 study analyzing HuCNS-SC human neural stem cells in treating chronic cervical spinal cord injury, according to Seeking Alpha.
Here are six insights:
1. StemCells reported the study Pathways' mid-stage results at the 2016 American Spinal Injury Association meeting in Philadelphia.
2. Five patients of six patients in Cohort 1 demonstrated muscle strength improvements at six months.
3. Four patients of six patients exhibited enhanced performance on dexterity and fine motor skills test.
4. Four patients of six patients demonstrated improvement in the level of cord injury measured by the International Standards for Neurological Classification of SCI.
5. The company will report 12-month data later this quarter.
6. StemCells has enrolled 19 patients of 40 patients in the study. They expect to complete the study in 2017.